Is NERV or NEUP more undervalued in 2026?

CirclFi compares Minerva Neurosciences, Inc (NERV) and Neuphoria Therapeutics Inc. (NEUP) using 13 institutional-grade valuation models. NERV has a Quality of Company score of 3.4/10 while NEUP scores 5.4/10.

Which is a better buy — NERV or NEUP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NERV and NEUP valuations compare?

NERV at $4.91 and NEUP at $5.31 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NERV vs NEUP Valuation Comparison 2026 — Intrinsic Value Analysis

NERV

Pharmaceutical Preparations

Minerva Neurosciences, Inc

Quality

3.4

out of 10

Value Trap

SAFE

Price

$4.91

Last close

Models

6/13

Active

NEUP

Pharmaceutical Preparations

Neuphoria Therapeutics Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$5.31

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	NERV Fair Value	NERV Upside	NEUP Fair Value	NEUP Upside
Bayesian DCF	Intrinsic	$1.70	-65.3%	$3.75	-29.4%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.14	-97.6%	$0.62	-88.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$11.74	+139.1%	$5.63	+6.0%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NERV vs NEUP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NERV vs NEUP — Which Stock Is More Undervalued?

NEUP scores higher with a 5.4/10 quality rating vs NERV's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Minerva Neurosciences, Inc (NERV) and Neuphoria Therapeutics Inc. (NEUP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NERV currently trades at $4.91 with a QOC of 3.4/10, while NEUP trades at $5.31 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).